These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25680954)

  • 1. Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
    Colussi O; Voron T; Pozet A; Hammel P; Sauvanet A; Bachet JB; Vaillant JC; Rougier P; Nordlinger B; Berger A; Coriat R; Dousset B; Malka D; André T; Paye F; Aparicio T; Locher C; Cojean Zeleck D; Tchinou L; Bonnetain F; Taieb J
    Eur J Surg Oncol; 2015 Apr; 41(4):520-6. PubMed ID: 25680954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
    Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
    Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
    J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
    Kim K; Chie EK; Jang JY; Kim SW; Han SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
    Am J Clin Oncol; 2016 Aug; 39(4):346-9. PubMed ID: 24755662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
    Sakabe R; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakashima A; Ohge H; Sueda T; Hiyama E
    Ann Surg Oncol; 2012 Sep; 19(9):3072-80. PubMed ID: 22322954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ampulla of Vater carcinoma in real-world clinical practice: a case series.
    Giuliani J; Piacentini P; Bonetti A
    Tumori; 2015 Jun; 101(3):e75-8. PubMed ID: 25908045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.
    Palta M; Patel P; Broadwater G; Willett C; Pepek J; Tyler D; Zafar SY; Uronis H; Hurwitz H; White R; Czito B
    Ann Surg Oncol; 2012 May; 19(5):1535-40. PubMed ID: 22045467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
    Kawabata Y; Nishi T; Kidani A; Tajima Y
    Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.
    Baghmar S; Agrawal N; Kumar G; Bihari C; Patidar Y; Kumar S; Chattopadhyay TK; Panda D; Arora A; Pamecha V
    J Gastrointest Cancer; 2019 Sep; 50(3):361-369. PubMed ID: 29464529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
    Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
    Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
    J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection.
    Fujimoto T; Ohtsuka T; Date K; Kimura H; Matsunaga T; Mori Y; Miyasaka Y; Mochidome N; Oda Y; Nakamura M
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):489-96. PubMed ID: 27273680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study.
    Robert PE; Leux C; Ouaissi M; Miguet M; Paye F; Merdrignac A; Delpero JR; Schwarz L; Carrere N; Muscari F; Gayet B; Dussart D; Hamy A; Regenet N
    Pancreas; 2014 Jul; 43(5):692-7. PubMed ID: 24713843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
    Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
    Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma.
    Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Jang JY; Kim SW; Kang GH; Yoon YB
    Ann Surg Oncol; 2007 Nov; 14(11):3195-201. PubMed ID: 17710498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
    Kang J; Lee W; Shin J; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Park SY; Kim SC
    Langenbecks Arch Surg; 2022 May; 407(3):1091-1097. PubMed ID: 35013798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma.
    Demirci NS; Ozdemir NY; Erdem GU; Bozkaya Y; Yazici O; Zengin N
    Bratisl Lek Listy; 2018; 119(3):180-186. PubMed ID: 29536748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.